Title:
COMBINATION THERAPY OF CHIMERIC ANTIGEN RECEPTOR AND HGF-NEUTRALIZING ANTIBODY
Document Type and Number:
WIPO Patent Application WO/2023/200266
Kind Code:
A1
Abstract:
The present invention relates to a chimeric antigen receptor (CAR) therapy comprising a population of immune effector cells expressing CARs to be used, in combination with a neutralizing antibody binding a neutralizable epitope of HGF, in cancer treatment for a subject. Combination with an HGF neutralizing antibody enhances treatment effects on the interaction of cancer cells and the immune system such that anti-cancer effects of CAR-T cell therapeutic agents are increased, and thus the present invention can be effectively used for treatment of solid cancer and hematological cancer.
Inventors:
SONG SEONG WON (KR)
LEE SONG JAE (KR)
JEON YEONG HA (KR)
JU AN NA (KR)
LEE NA RIM (KR)
KIM MIN GU (KR)
KIM MIN JOO (KR)
LEE SONG JAE (KR)
JEON YEONG HA (KR)
JU AN NA (KR)
LEE NA RIM (KR)
KIM MIN GU (KR)
KIM MIN JOO (KR)
Application Number:
PCT/KR2023/004996
Publication Date:
October 19, 2023
Filing Date:
April 13, 2023
Export Citation:
Assignee:
CELLABMED INC (KR)
International Classes:
A61K39/395; A61K35/17; A61K39/00; A61P35/00; C07K14/705; C07K14/725; C07K16/22; C07K16/28
Foreign References:
| KR20170142995A | 2017-12-28 | |||
| KR100556660B1 | 2006-03-10 |
Other References:
MANISH CHARAN; PIYUSH DRAVID; MAREN CAM; ANTHONY AUDINO; AMY C. GROSS; MICHAEL A. ARNOLD; RYAN D. ROBERTS; TIMOTHY P. CRIPE; ALEXA: "GD2‐directed CAR‐T cells in combination with HGF‐targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC., US, vol. 146, no. 11, 6 November 2019 (2019-11-06), US , pages 3184 - 3195, XP071290684, ISSN: 0020-7136, DOI: 10.1002/ijc.32743
KIM HYORI, HONG SUNG HEE, KIM JUNG YONG, KIM IN-CHULL, PARK YOUNG-WHAN, LEE SONG-JAE, SONG SEONG-WON, PARK GUNWOO, KIM TAE MIN, KI: "Preclinical development of a humanized neutralizing antibody targeting HGF", EXPERIMENTAL & MOLECULAR MEDICINE, vol. 49, no. 3, pages e309 - e309, XP093098245, DOI: 10.1038/emm.2017.21
KIM KIWAN, GWAK HO-SHIN, HAN NAYOUNG, HONG EUN KYUNG, CHOI BEOM K., LEE SANGEUN, CHOI SOYOUNG, PARK JU-HWANG, SEOK JI-HYE, JEON YE: "Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study", FRONTIERS IN IMMUNOLOGY, vol. 12, XP093098252, DOI: 10.3389/fimmu.2021.715000
SEO YOON-SEOK: "CellabMed announces ‘HGF antibody + IL13Rα2 CAR-T’ ASGCT", BIOSPECTATOR, 19 May 2022 (2022-05-19), XP093098256, Retrieved from the Internet
KIM HYORI, HONG SUNG HEE, KIM JUNG YONG, KIM IN-CHULL, PARK YOUNG-WHAN, LEE SONG-JAE, SONG SEONG-WON, PARK GUNWOO, KIM TAE MIN, KI: "Preclinical development of a humanized neutralizing antibody targeting HGF", EXPERIMENTAL & MOLECULAR MEDICINE, vol. 49, no. 3, pages e309 - e309, XP093098245, DOI: 10.1038/emm.2017.21
KIM KIWAN, GWAK HO-SHIN, HAN NAYOUNG, HONG EUN KYUNG, CHOI BEOM K., LEE SANGEUN, CHOI SOYOUNG, PARK JU-HWANG, SEOK JI-HYE, JEON YE: "Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study", FRONTIERS IN IMMUNOLOGY, vol. 12, XP093098252, DOI: 10.3389/fimmu.2021.715000
SEO YOON-SEOK: "CellabMed announces ‘HGF antibody + IL13Rα2 CAR-T’ ASGCT", BIOSPECTATOR, 19 May 2022 (2022-05-19), XP093098256, Retrieved from the Internet
Attorney, Agent or Firm:
PARK, Jong Hyeok (KR)
Download PDF:
Previous Patent: EXTENSION-TYPE DISPLAY DEVICE
Next Patent: COMBINATION THERAPY OF CHIMERIC ANTIGEN RECEPTOR AND HGF BINDING INHIBITOR SUBSTANCE
Next Patent: COMBINATION THERAPY OF CHIMERIC ANTIGEN RECEPTOR AND HGF BINDING INHIBITOR SUBSTANCE